Amgen smashed Wall Street's second-quarter expectations late Tuesday. Amgen stock topped a buy zone Wednesday.
Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash
Licensing
Amgen (AMGN) stock popped Wednesday on what one analyst called an "impressive" quarter featuring double-digit growth for nearly two dozen of its products. The best growth came from Uplizna, a treatment for several rare autoimmune conditions. Sales nearly doubled, rocketing 90% to $335 million. Meanwhile, revenue from the company's biggest moneymaker, cholesterol drug Repatha, surged 37% to $953 million. Both…
The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1…
Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.
Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall…
Abbott stock jumped early Thursday on better-than-expected second-quarter metrics. The company also raised its profit view.
AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS
With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis (MS) portfolio, Biogen is…
